BAMF
RNAM

BI Asset Management Fondsmaeglerselskab’s Avidity Biosciences RNAM Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,650
Closed -$78K – 884
2025
Q1 		$78K Sell
2,650
-52,463
-95% -$1.63M ﹤0.01% 720
2024
Q4 		$1.6M Buy
+55,113
New +$2.3M 0.02% 418

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's RNAM Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 2,650 shares — an estimated $78K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in RNAM in Q4 2024 and held it in 2 quarters. The position peaked at $1.6M in Q4 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 2,650 Avidity Biosciences shares in Q2 2025, an estimated $78K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Avidity Biosciences in Q4 2024 and held it in 2 quarters.
  • BI Asset Management Fondsmaeglerselskab's Avidity Biosciences position peaked at $1.6M in Q4 2024.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.